Nigeria Launches Twice-Yearly HIV Prevention Injection in Eight States
Nigeria has taken a significant step forward in its fight against HIV/AIDS with the introduction of a groundbreaking twice-yearly injectable drug, Lenacapavir (LEN). The rollout, which began in eight states and the Federal Capital Territory (FCT), aims to expand access to innovative HIV prevention methods and reduce the burden of the epidemic in the country.
The states benefiting from the initiative include Anambra, Ebonyi, Gombe, Kwara, Akwa Ibom, Cross River, Benue, and the FCT. This effort is supported by key partners such as the Global Fund and the World Health Organization (WHO), which endorsed the drug globally in July 2025. The National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme (NASCP), Dr. Adebobola Bashorun, highlighted that the rollout plan was informed by program data and stakeholder collaboration.
Lenacapavir, while not a cure for HIV, is a preventive measure designed to complement existing options such as oral pre-exposure prophylaxis (PrEP) and long-acting injectable cabotegravir. Unlike daily HIV prevention pills, Lenacapavir requires only two injections per year, making it one of the longest-acting prevention methods available. This innovation addresses a critical challenge in HIV prevention: adherence. Daily pills can be difficult to maintain due to stigma, forgetfulness, or limited access to healthcare.
A Game-Changer for Prevention
Dr. Temitope Ilori, Director-General of the National Agency for the Control of AIDS (NACA), emphasized that while global trials suggest Lenacapavir is largely safe, it is not recommended for pregnant women due to insufficient evidence. “LenPrEP is considered very safe based on global studies, but it is crucial to note that this is a preventive intervention, not a treatment,” she clarified.
The Minister of State for Health and Social Welfare, Dr. Iziaq Salako, revealed that Nigeria was chosen as one of nine early adopter countries by the Global Fund after expressing interest in March 2025. Approximately 52,000 doses have been allocated to support the rollout, with the first batch of 11,520 doses already delivered. The second tranche is expected in May, followed by a third in October 2026.
Lenacapavir is intended for HIV-negative individuals at substantial risk of infection, including those with HIV-positive partners, individuals with multiple partners, sex workers, men who have sex with men, and people who inject drugs. By reducing the frequency of administration, this drug could significantly improve protection rates and support global efforts to end HIV/AIDS as a public health threat by 2030.
Nigeria’s HIV Epidemic: A Persistent Challenge
Nigeria is home to approximately 1.9 to two million people living with HIV, making it the country with the second-largest HIV epidemic in the world. The national prevalence rate stands at 1.4% among adults aged 15-49, with regional variations. The South-South zone and specific vulnerable populations bear the highest burden.
While the introduction of Lenacapavir is a welcome development, health officials have urged caution, stressing that it should not be seen as a license for risky behavior. “We encourage those at risk to take advantage of this opportunity and utilize this important intervention,” Dr. Salako said.
Calls for Local Production and Further Research
The rollout has also sparked calls for local production of the drug under licensing agreements with patent holders. This move would ensure mass production and affordability for the majority of Nigerians. Historically, Nigeria has faced challenges with fraudulent claims of HIV cures and exploitative practices by some non-governmental organizations. Stakeholders emphasize the need for transparency and scientific rigor in advancing HIV research and interventions.
Dr. Salako and other leaders have called for intensified efforts to develop a home-grown cure for HIV, reducing dependency on international donors and foreign aid. “Any success in this regard will not only benefit Nigeria but humanity as a whole,” he noted. Collaborative efforts involving federal and state governments, non-governmental organizations, and the private sector are crucial to achieving zero new HIV cases by 2030.
Looking Ahead
Nigeria has made significant progress in its HIV awareness campaigns and efforts to reduce stigma against those living with the disease. However, the journey is far from over. The introduction of Lenacapavir marks a pivotal moment in the country’s fight against HIV/AIDS, offering hope for expanded prevention and improved outcomes for at-risk populations.
As Nigeria moves forward with this initiative, sustained collaboration across all sectors of society will be essential to ensure the success of the rollout and the ultimate goal of ending AIDS by 2030.
Reported by Nexio News
